Larimar Therapeutics
open label extension trial initiation expected in key eligibility criteria subcutaneous injections of | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
15 of 44
Related slides by other companies
Ocuphire Pharma
Results
March 2021
objectives and key eligibility criteria | Ocuphire Pharma
Ocuphire Pharma
Investor Day
January 2022
key eligibility criteria in zeta | Ocuphire Pharma
Ocuphire Pharma
Results
June 2021
objectives and key eligibility criteria secondary component individually conditions exclusion | Ocuphire Pharma
Heliogen
Investor Day
October 2022
key commercial and execution milestones | Heliogen
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights